Profile data is unavailable for this security.
About the company
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
- Revenue in USD (TTM)47.05m
- Net income in USD-160.60m
- Incorporated2022
- Employees106.00
- LocationScilex Holding Co960 San Antonio RoadPALO ALTO 94303United StatesUSA
- Phone+1 (650) 516-4310
- Fax+1 (302) 636-5454
- Websitehttps://www.scilexholding.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CorMedix Inc | 0.00 | -50.24m | 226.98m | 82.00 | -- | 3.91 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Sanara Medtech Inc | 68.00m | -4.89m | 238.23m | 107.00 | -- | 5.50 | -- | 3.50 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 238.71m | 137.00 | -- | 1.88 | -- | 2.65 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -25.20 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 279.92m | 597.00 | -- | -- | -- | 1.18 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | 396,390.30 | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Procaps Group SA | 414.10m | 52.20m | 282.06m | 5.50k | 4.80 | 7.16 | 4.05 | 0.6812 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 289.18m | 159.00 | -- | 7.11 | -- | 3.21 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 308.37m | 377.00 | -- | -- | -- | 1.80 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 318.15m | 100.00 | -- | 210.98 | -- | 35.70 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Scilex Holding Co | 47.05m | -160.60m | 326.14m | 106.00 | -- | -- | -- | 6.93 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -63.93m | 335.05m | 45.00 | -- | 2.96 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Bio Essence Corp | 551.51k | -812.66k | 369.71m | 12.00 | -- | -- | -- | 670.37 | -0.0225 | -0.0157 | 0.015 | -0.0378 | 0.4912 | -- | 1.53 | 45,959.17 | -72.37 | -46.34 | -- | -- | 31.29 | 33.89 | -147.35 | -111.21 | -- | -47.73 | 3.39 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
| Precigen Inc | 5.44m | -96.91m | 371.06m | 202.00 | -- | 3.79 | -- | 68.22 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Anika Therapeutics Inc | 169.26m | -76.83m | 376.05m | 357.00 | -- | 1.80 | -- | 2.22 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 395.11m | 1.60k | -- | 0.5951 | -- | 0.3333 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 413.87m | 99.00 | -- | 2.02 | -- | 6.73 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Data as of Jul 03 2024. Currency figures normalised to Scilex Holding Co's reporting currency: US Dollar USD
12.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 7.42m | 4.09% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.55m | 3.06% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.95m | 2.18% |
| Millennium Management LLCas of 31 Mar 2024 | 1.07m | 0.59% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.05m | 0.58% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 885.30k | 0.49% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 676.02k | 0.37% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 627.04k | 0.35% |
| Rafferty Asset Management LLCas of 31 Mar 2024 | 620.13k | 0.34% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 580.20k | 0.32% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
